A MULTICENTER PHASE II TRIAL OF NAB-PACLITAXEL IN COMBINATION WITH CAPЕCTABINE IN PATIENTS (PTS) WITH HER-2 NEGATIVE AND TRIPLE NEGATIVE ADVANCED BREAST CANCER (ABC): AN INTERIM ANALYSIS

M. Ciccarese1, L. Orlando, P. Fedele3, P. Schiavone2, E. Masetti2, P. Cilenti5, M. Aieta6, G. Bozza6, M.R.C. Forcignanò1, A. Febbraro7, R. Bordonaro8, S. Romito9, A. Rinaldi10, N. Borsellino11, F. Riccardi12, S. Pisconti13, V. Lorusso14, G. Colucci15, S. Cinieri16

1Oncology Dept., Ospedale Vito Fazzi, Lecce, ITALY
2Ospedale Perrino, Oncologia Brindisi, Brindisi, ITALY
3Oncology & Breast Unit, Antonio Perrino Hospital, Brindisi, ITALY
4Oncology, Casa Sollievo della Sofferenza, S. Giovanni Rotondo, ITALY
5Oncology Dept., Casa Sollievo della Sofferenza, S. Giovanni Rotondo, ITALY
6Medical Oncology, Department of Medical Oncology, National Institute of Cancer, Rionero in Vulture (PZ), Rionero (PZ), ITALY
7Oncology, Ospedale Fatebenefratelli Benevento, Benevento, ITALY
8Oncology, “G. Battista” Hospital, Catania, ITALY
9Oncology, “Garibaldi Desima Superiore” Hospital, Catania, ITALY
10Oncology, Presidio Ospedaliero Occidentale, Catanzaro, ITALY
11Oncology, “Buccheri la Ferla Fatebenefratelli” Hospital, Palermo, ITALY
12Oncology, Ospedale Cardarelli, Naples, ITALY
13Oncology, “S. G. Moscati” Hospital, Taranto, ITALY
14Oncology, “Giovanni Paolo II” IRCCS, Bari, ITALY
15Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, ITALY
16Oncology, “Sen. Perrino” Hospital, Brindisi, ITALY

Aim: ABC remains a therapeutic challenge in spite of the use of emerging new drugs. Nab-paclitaxel has better efficacy and no risk of hypersensitivity reactions when compared to paclitaxel. We studied the association of nab-paclitaxel and capécitabine in a novel schedule as I line treatment in a population of HER2 negative and triple-negative ABC. An interim analysis was preplanned at 54 enrolled pts.

Methods: Nab-paclitaxel 150 mg/m² was administered day 1 and 8 out of 21 days in combination with capécitabine at 825 mg/m² twice daily, day 1-14 out of 21 days as first line therapy for HER2 negative ABC. The primary endpoints of the study are response rate (RR) and progression-free survival (PFS), secondary endpoints are toxicity and overall survival (OS).

Results: Sixty five pts were enrolled from 11 centers, 59 pts (90.8%) evaluable for RR and PFS (ITT), 58 pts evaluable (89.3%) for toxicity. Median age was 56 years (34-77), 21 (32.3%) pts had triple-negative ABC, 44 pts (67.7%) hormone receptor positive ABC. Median number of metastatic site was 2 (range 1-5), visceral disease was present in 48 pts (73.9%). Median number of cycles was 6 (range 1-8). CR were 4 (6.8%), PR 31 (52.5%), for an overall RR (ORR) of 59.3%. SD was observed in 15 pts (25.4%), PD in 9 pts (15.3%). In the subpopulation of triple-negative ABC was 50%. Median PFS for all pts was 43 weeks (26-48), 25 weeks (11-37) in triple-negative pts. Hematological toxicity Grade 3/4 was seen in 12/3 pts (18.5%/4.6%) (neutropenia G3/4 10/1 pts (15.4%/1.5%) and febrile neutropenia 2 pts (3%), respectively). Non-hematological toxicity grade 3/4 was seen in 11/10 pts (17%/15.4%), particularly neuropathy G3/4 1/0 (1.5%/0%).

Conclusions: Significant clinical activity and good tolerability was seen from the combination of nab-paclitaxel and capécitabine in HER2 negative ABC. The study is ongoing, but data provide a basis to consider this regimen for further evaluation in phase III trials.

Disclosure: All authors have declared no conflicts of interest.